Hydroxychloroquine (HCQ) treatment for hospitalized patients with COVID-19

Tsanovska et al., Infectious Disorders - Drug Targets, doi:10.2174/1871526522666220303121209

Mar 2022

Source PDF All Studies Meta AnalysisMeta

PSM prospective study of 260 COVID-19 patients in Bulgaria, showing lower mortality, ventilation, and ICU admission with HCQ treatment.

Important missing comments or errors? Let us know.

risk of death, 57.9% lower, RR 0.42, p = 0.03, treatment 8 of 70 (11.4%), control 19 of 70 (27.1%), NNT 6.4, propensity score matching.

risk of mechanical ventilation, 73.9% lower, RR 0.26, p < 0.001, treatment 6 of 70 (8.6%), control 23 of 70 (32.9%), NNT 4.1, propensity score matching.

risk of ICU admission, 70.4% lower, RR 0.30, p < 0.001, treatment 8 of 70 (11.4%), control 27 of 70 (38.6%), NNT 3.7, propensity score matching.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Tsanovska et al., 3 Mar 2022, prospective, Bulgaria, peer-reviewed, 8 authors, study period 6 November, 2020 - 28 December, 2020.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0